Compositions and methods for treating retinal degradation
The present disclosure relates to compositions and methods for treating retinal damage and/or retinal degradation. More specifically, this disclosure relates to methods for treating degradation of the retinal pigment epithelium by administering compositions comprising a nucleoside and/or a nucleoside or nucleotide reverse transcriptase inhibitor.
1. A method of treating a condition selected from Parkinson's disease, Alzheimer's disease, and multiple sclerosis comprising administering to a subject in need thereof a compound selected from:
(i) a compound having the structure of formula I
or a pharmaceutically acceptable salt thereof;
(ii) a compound having the structure of formula II
(iii) a compound having the structure of formula III, or a pharmaceutically acceptable salt thereof;
(iv) a compound having the structure of formula IV,
wherein n is 10 to 20;
(v) a compound having the structure of formula V
(vi) stavudine (d4T);
(vii) lamivudine (3TC);
(viii) cordycepin;
(ix) azidothymidine (AZT);
(x) abacavir (ABC); and
(xi) a combination thereof.
2. The method of claim 1 , wherein the compound is selected from:
(i) the compound having the structure of formula I
or a pharmaceutically acceptable salt thereof;
(ii) the compound having the structure of formula II
(iii) the compound having the structure of formula III, or a pharmaceutically acceptable salt thereof;
(iv) the compound having the structure of formula IV,
wherein n is 10 to 20;
(v) a compound having the structure of formula V
(vi) a combination thereof.
3. The method of claim 1 , wherein n is 11.
4. The method of claim 1 , wherein the compound is selected from:
(i) the compound having the structure of formula
or a pharmaceutically acceptable salt thereof;
(ii) the compound having the structure of formula II
and
(iii) a compound having the structure of formula V
and
(iv) a combination thereof.
5. The method of claim 1 , wherein the compound is selected from:
(i) the compound having the structure of formula
or a pharmaceutically acceptable salt thereof;
(ii) a compound having the structure of formula V
and
(iii) a combination thereof.
6. The method of claim 1 , wherein the compound is a compound having the structure of formula I
or a pharmaceutically acceptable salt thereof.
7. The method of claim 1 , wherein the compound is the compound having the structure of formula II:
8. The method of claim 1 , wherein the compound is the compound having the structure of formula V:
9. The method of claim 1 , wherein the compound is selected from
(vi) stavudine (d4T);
(vii) lamivudine (3TC);
(viii) cordycepin;
(ix) azidothymidine (AZT);
(x) abacavir (ABC); and
(xi) a combination thereof.
10. The method of claim 1 , wherein the method comprises administering a composition comprising the compound and a pharmaceutically acceptable carrier.
11. The method of claim 1 , wherein the condition is Parkinson's disease.
12. The method of claim 1 , wherein the condition is Alzheimer's disease.
13. The method of claim 1 , wherein the condition is multiple sclerosis.